Mein Warenkorb

Transferrin R

Transferrin R Molekülinformation

Englischer NameTransferrin receptor protein 1Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel15Target-AliasTFRC,T9,sTfR,Transferrin receptor protein 1,TR,Transferrin Receptor,P90,Transferrin Receptor (P90, CD71),CD71 Antigen,IMD46,CD71,TfR1,Trfr,TfR
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameTransferrin receptor protein 1
Target-AliasTFRC,T9,sTfR,Transferrin receptor protein 1,TR,Transferrin Receptor,P90,Transferrin Receptor (P90, CD71),CD71 Antigen,IMD46,CD71,TfR1,Trfr,TfR
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel15
Höchste Forschungs- und EntwicklungsphaseApproved

Transferrin R Produktliste

  • Attribut

    Protein (16)Cell (1)

  • Produktbibliothek

    Online (17)

  • Spezies

    Human (7)Cynomolgus (4)Mouse (4)Rat (2)

  • Etikett

    His Tag (7)His Tag & Avi Tag (4)Fc Tag (3)Tag Free (2)Fc Tag & Avi Tag (1)

  • Marker

    Unconjugated (8)Biotin-labeled (8)- (1)

Transferrin R Molekülhintergrund

CD antigen CD71 is also known as Transferrin receptor protein 1, TfR, sTfR, p90, TfR1, Trfr, which belongs to the peptidase M28 family and M28B subfamily. CD71 /TFR contains one PA (protease associated) domain. CD71 / TfR1 is required for iron delivery from transferrin to cells. CD71 is a potential new target in cases of human leukomia & lymphoma. CD71 /TFRC / TfR has been shown to interact with GABARAP and HFE.

Transferrin R Molekülalias

CD71,TFRC,TFR,sTfR,TfR1,Trfr,T9,p90

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Human apotransferrin (Sanquin Blood Supply Foundation)Phase 3 ClinicalSanquin Plasma Products Bvbeta-Thalassemia; Iron Metabolism Disorders
Details
Delpacibart braxlosiranAOC1020Phase 3 ClinicalAvidity Biosciences IncFoot-and-Mouth Disease; Muscular Dystrophies; Muscular Dystrophy, Facioscapulohumeral
Details
Delpacibart eteddesiranAOC-1001; AOC 1001Phase 3 ClinicalAvidity Biosciences IncGenetic Diseases, Inborn; Heredodegenerative Disorders, Nervous System; Muscular Atrophy; Muscular Diseases; Muscular Disorders, Atrophic; Muscular Dystrophies; Musculoskeletal Diseases; Myotonia; Myotonic Disorders; Myotonic Dystrophy; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Diseases
Details
TrontinemabRO-7126209; RG-6102Phase 3 ClinicalF. Hoffmann-La Roche LtdAlzheimer Disease
Details
CX-2029ABBV-2029; ABBV-CX-2029; CX-2029Phase 2 ClinicalAbbvie Inc, Cytomx Therapeutics IncCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours
Details
Zeleciment rostudirsenDYNE251Phase 2 ClinicalDyne Therapeutics IncMuscular Dystrophy, Duchenne
Details
AOC-1044AOC-1044; AOC 1044Phase 2 ClinicalAvidity Biosciences IncMuscular Dystrophy, Duchenne
Details
JR-446JR-446Phase 2 ClinicalJcr Pharmaceuticals Co Ltd, Medipal Holdings CorpMucopolysaccharidosis III
Details
JR-441JR-441Phase 2 ClinicalJcr Pharmaceuticals Co LtdMucopolysaccharidosis III
Details
Lepunafusp alfaJR-171Phase 2 ClinicalJcr Pharmaceuticals Co LtdMucopolysaccharidosis I
Details
PPMX-T003PPMX-T003Phase 2 ClinicalPerseus Proteomics IncLeukemia; Polycythemia Vera
Details
INA-03INA03Phase 1 ClinicalInatherysLeukemia; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
PRX012-TfRPRX012-TfRPhase 1 ClinicalProthenaAlzheimer Disease
Details
KK-2260KK2260; KK-2260Phase 1 ClinicalKyowa Kirin Co LtdEsophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
ABX-1100ABX-1100Phase 1 ClinicalAro Biotherapeutics CoGlycogen Storage Disease Type II
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Pabinafusp alfaJR-141ApprovedJcr Pharmaceuticals Co LtdJapanMucopolysaccharidosis IIJcr Pharmaceuticals Co Ltd2021-03-23Mucopolysaccharidosis II
Details

Produktrezensionen

Laden Sie mehr
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns